Our top pick for
Building a portfolio

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Frequency Therapeutics, Inc is a biotechnology business based in the US. Frequency Therapeutics shares (FREQ) are listed on the NASDAQ and all prices are listed in US Dollars. Frequency Therapeutics employs 83 staff and has a trailing 12-month revenue of around USD$37 million.
Our top pick for
Building a portfolio
Our top pick for
Beginners
Our top pick for
Active investors
52-week range | USD$7.335 - USD$58.37 |
---|---|
50-day moving average | USD$32.9556 |
200-day moving average | USD$31.1526 |
Wall St. target price | USD$23 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | USD$-0.6355 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Revenue TTM | USD$37 million |
---|---|
Gross profit TTM | USD$37 million |
Return on assets TTM | -7.06% |
Return on equity TTM | -14.74% |
Profit margin | -71.68% |
Book value | N/A |
Market capitalisation | USD$369.5 million |
TTM: trailing 12 months
There are currently 4.2 million Frequency Therapeutics shares held short by investors – that's known as Frequency Therapeutics's "short interest". This figure is 21.7% down from 5.3 million last month.
There are a few different ways that this level of interest in shorting Frequency Therapeutics shares can be evaluated.
Frequency Therapeutics's "short interest ratio" (SIR) is the quantity of Frequency Therapeutics shares currently shorted divided by the average quantity of Frequency Therapeutics shares traded daily (recently around 339019.70684039). Frequency Therapeutics's SIR currently stands at 12.28. In other words for every 100,000 Frequency Therapeutics shares traded daily on the market, roughly 12280 shares are currently held short.
However Frequency Therapeutics's short interest can also be evaluated against the total number of Frequency Therapeutics shares, or, against the total number of tradable Frequency Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Frequency Therapeutics's short interest could be expressed as 0.12% of the outstanding shares (for every 100,000 Frequency Therapeutics shares in existence, roughly 120 shares are currently held short) or 0.1349% of the tradable shares (for every 100,000 tradable Frequency Therapeutics shares, roughly 135 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Frequency Therapeutics.
Find out more about how you can short Frequency Therapeutics stock.
We're not expecting Frequency Therapeutics to pay a dividend over the next 12 months.
Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on harnessing the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. Its Progenitor Cell Activation approach, uses combinations of small molecules to activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in phase 2a clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. Frequency Therapeutics, Inc. has a licencse and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322. Frequency Therapeutics, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.
Steps to owning and managing SGLB, with 24-hour and historical pricing before you buy.
Steps to owning and managing SSD, with 24-hour and historical pricing before you buy.
Steps to owning and managing SQNS, with 24-hour and historical pricing before you buy.
Steps to owning and managing SFL, with 24-hour and historical pricing before you buy.
Steps to owning and managing AIHS, with 24-hour and historical pricing before you buy.
Steps to owning and managing ST, with 24-hour and historical pricing before you buy.
Steps to owning and managing SLCT, with 24-hour and historical pricing before you buy.
Steps to owning and managing EYES, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBSW, with 24-hour and historical pricing before you buy.
Steps to owning and managing SHG, with 24-hour and historical pricing before you buy.